DPCO List of 14 Formulations 2020

DPCO List of 14 Formulations 2020

NPPA HAS FIXED RETAIL PRICES OF 14 FORMULATIONS UNDER DRUGS (PRICES CONTROL) ORDER, 2013 RELATING TO 76TH AUTHORITY MEETING DATED 22.06.2020, complete information about DPCO List of 14 Formulations 2020 is here in the table.

In the 76th Authority Meeting of NPPA held on 22.06.2020, Fixed retail price of 14 formulations under DPCO Order 2013 vide S.O. 2150 dt. 30-06-2020. In DPCO List of 14 Formulations 2020, there has been covered very popular formulations dpco prices i.e. Clopidogrel Bisulphate + Aspirin Tablet DPCO price, dpco price of Glimepiride + Metformin Hydrochloride Tablet, Atorvastatin + Aspirin Capsule dpco rate, dpco price of Cilnidipine + Telmisartan Tablet, DPCO of Etoricoxib + Paracetamol Tablet, DPCO price of Tolperisone Hydrochloride + Diclofenac Sodium Tablet and many more for all see complete DPCO List of 14 Formulations 2020.

Notifications of DPCO List of 14 Formulations 2020

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)
Government of India Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals National Pharmaceutical Pricing Authority

New Delhi, 30 June, 2020


ORDER

S. O. 2150 (E) In exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail
price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit, and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
 

TABLE

Sl.
No.
Name of the Formulation / Brand NameStrengthUnitManufacturer & Marketing CompanyRetail Price (Rs.)
1Clopidogrel Bisulphate + Aspirin TabletEach uncoated bilayered tablet contains:
Clopidogrel Bisulphate IP Eq. to Clopidogrel 75 mg
Aspirin IP 75 mg
1 TabletM/s Akums Drugs & Pharmaceuticals Limited/ M/s Mylan Pharmaceuticals Pvt. Limited3.71
2Glimepiride + Metformin Hydrochloride TabletEach uncoated bilayered tablet contains: Glimepiride IP 3mg, Metformin Hydrochloride IP 1000mg (as prolonged-release
form)
1 TabletM/s Akums Drugs and Pharmaceuticals Ltd./M/s Emcure Pharmaceuticals Limited8.94
3Glimepiride + Metformin Hydrochloride TabletEach uncoated bilayered tablet contains: Glimepiride IP 4mg, Metformin Hydrochloride IP 1000mg (as prolonged-release
form)
1 TabletM/s Akums Drugs and Pharmaceuticals Ltd./M/s Emcure Pharmaceuticals Limited9.56
4Atorvastatin + Aspirin CapsuleEach Hard Gelatin Capsule contains:
Atorvastatin Calcium IP eq. Atorvastatin 10 mg (as Film Coated tablet)
Aspirin IP 75mg (as Gastro Resistant Tablet IP)
1 CapsuleM/s Micro Labs Limited2.42
5Atorvastatin + Aspirin CapsuleEach Hard Gelatin Capsule contains:
Atorvastatin Calcium IP eq. Atorvastatin 10 mg (as Film Coated tablet)
Aspirin IP 150mg (as two Gastro Resistant Tablet IP each 75mg)
1 CapsuleM/s Micro Labs Limited2.54
6Cilnidipine + Telmisartan Tablet (Telsartan –LN 80)Each film-coated tablet contains: Cilnidipine IP 10 mg, Telmisartan IP 80 mg1 TabletM/s Pure and Cure Healthcare Pvt. Ltd./ Dr. Reddy’s Laboratories
Limited
13.12
7Cilnidipine + Telmisartan Tablet (Telsartan –LN 40)Each film-coated tablet contains: Cilnidipine IP 10 mg, Telmisartan IP 40 mg1 TabletM/s Pure and Cure Healthcare Pvt. Ltd./ Dr. Reddy’s Laboratories
Limited
8.65
8Rosuvastatin + Aspirin +
Clopidogrel Capsule (Rozat Gold 10mg)
Each hard gelatin capsule
contains: Rosuvastatin Calcium IP Eq. to Rosuvastatin 10mg (As film coated Rosuvastatin Tablets IP)
Aspirin IP 75mg (As Aspirin Gastro-Resistant Tablets IP) Clopidogrel Bisulphate IP Eq. to Clopidogrel 75mg (As film
coated Clopidogrel Tablets IP)
1 CapsuleM/s Akums Drugs and
Pharmaceuticals Ltd / Dr. Reddy’s Laboratories Limited
11.48
9Rosuvastatin + Aspirin + Clopidogrel Capsule (Rozat Gold 20mg)Each hard gelatin capsule contains: Rosuvastatin Calcium IP Eq. to Rosuvastatin 20mg (As film coated Rosuvastatin Tablets IP)
Aspirin IP 75mg (As Aspirin Gastro-Resistant Tablets IP) Clopidogrel Bisulphate IP Eq. to
Clopidogrel 75mg (As film coated Clopidogrel Tablets IP)
1 CapsuleM/s Akums Drugs and Pharmaceuticals Ltd / Dr. Reddy’s Laboratories Limited17.46
10Glimepiride + Metformin Hydrochloride Tablet (Glimy M3 Forte)Each uncoated bilayered tablet contains:
Glimepiride IP 3mg, Metformin Hydrochloride IP
1000mg (as prolonged-release form)
1 TabletM/s Akums Drugs and Pharmaceuticals Ltd/ Dr. Reddy’s Laboratories Limited8.94
11Glimepiride + Metformin Hydrochloride Tablet (Glimy M4 Forte)Each uncoated bilayered tablet contains:
Glimepiride IP 4mg, Metformin Hydrochloride IP 1000mg(as prolonged-release form)
1 TabletM/s Akums Drugs and Pharmaceuticals Ltd / Dr. Reddy’s Laboratories Limited9.56
12Etoricoxib + Paracetamol TabletEach film-coated tablet contains: Etoricoxib IP 60mg, Paracetamol IP 325mg1 TabletM/s Pure and Cure Healthcare Pvt. Ltd. / M/s Zuventus Healthcare
Limited
5.58
13Tolperisone Hydrochloride + Diclofenac Sodium TabletEach film-coated bilayered tablet contains:
Tolperisone Hydrochloride IP 150mg,
Diclofenac Sodium IP 50mg
1 TabletM/s Pure and Cure Healthcare Pvt. Ltd. / M/s Zuventus Healthcare Limited13.42
14Cilnidipine + Metoprolol TabletEach film-coated bilayered tablet contains:
Cilnidipine IP 10mg, Metoprolol Succinate IP 23.75mg eq. to
Metoprolol Tartrate 25mg (in extended-release form)
1 TabletM/s Pure and Cure Healthcare Pvt. Ltd. /M/s Intas Pharmaceuticals Limited7.11

(a) The manufacturer of the above-mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table herein above.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above
i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO,

2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
PN/208/76/2020/F F. No. 8(76)/2020/D.P./NPPA-Div.-II

Sd/- (Prasenjit Das) Assistant Director

Related Posts

Darshan Singh

The author has 20 years of experience in the Pharmaceutical Manufacturing Companies. Have exposure to all audit documents for WHO-GMP, PIC/S, USFDA, Export documents, US-FDA documents, Validation of Pharma machinery, and Quality Control Instruments. Expert in Pharma Plant Setup and sale and acquisition of running pharma company.

https://www.laafon.com
× How can I help you?